News
Client MNRs and Landing Pages
Since 2004, brands have counted on Cision’s MultiVu to create and distribute their important news and marketing content to the world.
Let's talkSearch our recent client collaborations below:
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Nov 10, 2025Delivering High-Quality Care Support Where Children Thrive — At HomeNemours Children’s Health Launches Nation’s First Pediatric Advanced Care at Home Delivering High-Quality Care Support Where Children Thrive — At Home JACKSONVILLE, Fla. (Nov. XX, 2025) –...
Nov 10, 2025New campaign weaves science and storytelling to reframe obesity as a chronic diseaseLearn more about Pro Plan "Fueled By" Tan France Helps Unthread Obesity Bias as Part of Zepbound’s (tirzepatide) ‘Changing the Thread’ Collection New campaign weaves science and storytelling...
Nov 6, 2025Gilead Sciences, the PBC Foundation, and Friends of the PBC Foundation have launched “All the Feelings with PBC™”Learn more about Dilek’s story Gilead and PBC Foundation Collaborate with Berlin-based Artist and Los Angeles Film Maker to Tell Emotionally Complex Stories About People Living with Primary...
Nov 6, 2025Rock & Roll Hall of Famer Danny Seraphine & CTA headlines aftershow concertSupport Our Mission Asian Hall of Fame Unveils Iconic Induction 2025 Rock & Roll Hall of Famer Danny Seraphine & CTA headlines aftershow concert LOS ANGELES, Oct. 28, 2025 /PRNewswire/ –...
Nov 6, 2025Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved CAPLYTA® (lumateperone) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder (MDD) in adults.FDA approval of CAPLYTA® (lumateperone) has potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder CAPLYTA®, in combination with an oral...
Connect with us: